Bristol Myers Squibb (BMY) Operating Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Operating Expenses for 18 consecutive years, with $8.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 15.33% year-over-year to $8.9 billion in Q2 2026; TTM through Jun 2026 was $37.3 billion, a 9.32% decrease from a year earlier, with the FY2025 full-year figure at $38.9 billion, down 31.43% from the prior year.
• Operating Expenses was $8.9 billion for Q2 2026 at Bristol Myers Squibb, up from $8.2 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $23.4 billion in Q1 2024 and troughed at $8.2 billion in Q1 2025.
• A 5-year average of $10.4 billion and a median of $9.7 billion in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 172.92% in 2024 and slumped 64.8% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $9.5 billion in 2022, then gained by 2.68% to $9.8 billion in 2023, then climbed by 24.12% to $12.2 billion in 2024, then dropped by 9.33% to $11.0 billion in 2025, then decreased by 19.44% to $8.9 billion in 2026.
• The last three Operating Expenses figures came in at $8.9 billion (Q2 2026), $8.2 billion (Q1 2026), and $11.0 billion (Q4 2025), per Business Quant data.